The Relationship between Steroidogenic Factor 1 and DAX-1 Expression and in Vitro Gonadotropin Secretion in Human Pituitary Adenomas

2001 ◽  
Vol 86 (6) ◽  
pp. 2476-2483 ◽  
Author(s):  
S. J. B. Aylwin
2001 ◽  
Vol 86 (6) ◽  
pp. 2476-2483
Author(s):  
S. J. B. Aylwin ◽  
J. P. Welch ◽  
C. L. Davey ◽  
J. F. Geddes ◽  
D. F. Wood ◽  
...  

The orphan nuclear receptors, steroidogenic factor 1 (SF-1) and DAX-1, are involved in gonadotroph differentiation, and SF-1 has been shown to activate the LH-β and glycoprotein hormone α-subunit (αGSU) gene promoters. Pituitary adenomas from 34 patients [13 somatotroph tumors, 4 prolactinomas, and 17 clinically nonfunctioning pituitary adenomas (NFPAs)] were enzymatically dispersed and cultured in vitro for 48 h. Tissue culture medium was collected and assayed for LH, FSH, and αGSU; messenger RNA was extracted from adherent cells, and expression of SF-1 and DAX-1 messenger RNA was determined by RT-PCR and verified by direct DNA sequencing. The presence of DAX-1 protein in tumor tissue was confirmed by immunocytochemistry. DAX-1 was demonstrated in all NFPAs, 7 of 13 somatotroph tumors and 0 of 4 prolactinomas. SF-1 expression occurred in 8 of 16 NFPAs, 4 of 12 somatotroph tumors, and 1 of 4 prolactinomas. LH secretion in vitro was greater in NFPAs that were SF-1 positive (P < 0.05). Neither FSH secretion nor αGSU secretion in vitro were significantly related to the expression of SF-1 or DAX-1. SF-1-positive somatotroph tumors immunostained positively for LH-β and/or FSH-β and secreted gonadotropins in vitro. SF-1 expression is associated with the in vitro secretion of LH by NFPAs. A proportion of somatotroph tumors also express SF-1 and DAX-1 and secrete gonadotropin hormones in vitro.


1981 ◽  
Vol 98 (1) ◽  
pp. 14-23 ◽  
Author(s):  
R. A. Prysor-Jones ◽  
S.J. Kennedy ◽  
J. P. O'Sullivan ◽  
J. S. Jenkins

Abstract. The effect of bromocriptine and somatostatin on hormone secretion and the ultrastructure of human pituitary adenomas was studied in vitro. Prolactin secretion was inhibited by bromocriptine in 3 out of 10 prolactin-secreting tumours and in explants from 2 normal pituitaries. GH secretion was reduced by bromocriptine in 4 out of 6 GH-secreting adenomas but was not affected by the drug in the incubations of normal pituitaries. Somatostatin inhibited GH secretion in 2 out of 5 pituitary adenomas and the effect was comparable with that of bromocriptine. Incubation of prolactin-secreting adenomas with oestradiol for as long as 24 days produced no change in hormone secretion. Examination of tumour explants by electron microscopy showed that somatostatin and bromocriptine produced accumulation of secretion granules but no changes in the secretory organelles. Long term bromocriptine treatment of 'nude' athymic mice bearing xenografts of human pituitary adenomas suppressed hormone secretion and produced some increase in secretion granules but there were no morphological changes in the secretory organelles or other vital structures of the adenoma cells.


1979 ◽  
Vol 49 (5) ◽  
pp. 737-741 ◽  
Author(s):  
F. PEILLON ◽  
F. CESSELIN ◽  
D. BRESSION ◽  
N. ZYGELMAN ◽  
A.M. BRANDI ◽  
...  

Tumor Biology ◽  
1993 ◽  
Vol 14 (1) ◽  
pp. 59-68 ◽  
Author(s):  
Brunella Caronti ◽  
Guido Palladini ◽  
Maria Gabriella Bevilacqua ◽  
Elisa Petrangeli ◽  
Bernardo Fraioli ◽  
...  

2002 ◽  
Vol 57 (4) ◽  
pp. 449-455 ◽  
Author(s):  
Massimo Giusti ◽  
Liliana Bocca ◽  
Tullio Florio ◽  
Alessandro Corsaro ◽  
Renato Spaziante ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document